<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489914</url>
  </required_header>
  <id_info>
    <org_study_id>TAVI-STAR</org_study_id>
    <nct_id>NCT04489914</nct_id>
  </id_info>
  <brief_title>Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement</brief_title>
  <official_title>Observational Study on the Application of High-Flow Therapy in the Postinterventional Follow-up Care of Patients With Percutaneous Interventional Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drägerwerk AG &amp; Co. KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drägerwerk AG &amp; Co. KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous catheter-assisted valve replacement in aortic position (TAVI) for patients with&#xD;
      high perioperative risk has become a standard method in recent years. In addition to the&#xD;
      detection of bleeding and cardiac rhythm complications, follow-up care is mainly focused on&#xD;
      the monitoring of respiratory parameters after an operation under intubation anesthesia or&#xD;
      deep analgosedation. In addition to normal oxygen therapy, non-invasive ventilation and, in&#xD;
      case of weaning failure, renewed tracheal intubation in the first 24 h after TAVI have been&#xD;
      considered. High flow oxygen therapy (HFOT) now provides a good opportunity to treat patients&#xD;
      with a warmed and humidified air-oxygen mixture and to independently control the oxygen&#xD;
      content in the inhaled air and the flow in the pharyngeal area.&#xD;
&#xD;
      The aim of the Study is to investigate the Change in oxygenation after high-flow oxygen&#xD;
      therapy as a measure of weaning success in postinterventional patients after TAVI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">April 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Horovitz index</measure>
    <time_frame>24 hours</time_frame>
    <description>The Gradient of paO2/FiO2 will be determined after TAVI via blood gas analysis</description>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-Flow Oxygen Therapy</intervention_name>
    <description>high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        University hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High-flow oxygen therapy after TAVI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients without consent&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Graf, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

